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Introduction 
Signal transduction through CD28 plays an important role 
in regulating the initial response of a T cell to antigen. Two 
distinct CD28 ligands, B7-1 (CD80) and B7-2 (CD86), have 
been identified. These ligands also bind to CTLA-4, a re- 
ceptor closely related to CD28 that is expressed on acti- 
vated T cells. Recent studies designed to examine the 
individual roles of B7-1 and B7-2 in the regulation of an 
in vivo immune response have demonstrated that costimu- 
lation through CD28, CTLA-4, or both is more complex 
than previously believed. In vivo, the costimulatory ligands 
B7-1 and B7-2 appear to differ in their ability to potentiate 
the differentiation of T helper (Th) cells into either type 1 
(Thl) cells, which direct cell-mediated immunity, or type 
2 (Th2) cells, which support a humoral immune response. 
These results have important implications for our under- 
standing of in vivo immune responses as well as for strate- 
gies of immunotherapy involving the CD28 costimuiatory 
pathway. 
The Role of Costimulatory Receptors in the 
Initiation of an immune Response 
An antigen-specific T cell immune response is initiated as 
a result of interaction between a T cell receptor (TCR) and 
antigen-major histocompatibility complex (MHC) com- 
plexes expressed on the surface of an antigen-presenting 
cell (APC). However, while TCR signal transduction is nec- 
essary for the activation of a naive T cell, TCR ligation 
alone is not sufficient o initiate an immune response under 
most circumstances (Figure 1). For optimal activation of 
a naive T cell, additional or costimulatory signals are 
needed. Activation through the TCR in the presence of 
such costimulatory signals results in T cell clonal expan- 
sion and in the induction of effector functions such as 
lymphokine production. Interaction of naive T cells with 
antigen in the absence of a costimulatory signal can result 
in T cell unresponsiveness or death. In this model, T cell 
costimulatory signals play a critical role in dictating the 
subsequent fate of a T cell that initiates a response to 
antigen. 
The BZICD28 Activation Pathway Transmits 
a Costimulatory Signal 
Work over the last several years has demonstrated that 
CD28 is one of the major costimulatory receptors on the 
surface of a resting T cell (for review see Allison, 1994). 
Signal transduction through CD28 synergizes with TCR 
signal transduction to augment both interleukin-2 (IL-2) 
production and proliferation of naive T cells. Blockade of 
the CD28 signal transduction pathway by noncross-linking 
monovalent antibody fragments can render T cells hypore- 
sponsive to subsequent challenge with antigen. Several 
years ago, the B cell activation antigen B7-1 (CD80) was 
found to be a ligand for CD28. B7-1 was subsequently 
found to be expressed as an activation antigen on a variety 
of additional APCs, including dendritic cells and mono- 
cytes. 
In addition to CD28, B7-1 can bind to the T cell activation 
antigen CTLA-4. CTLA-4 binds to B7-1 with -20-fold 
higher avidity than CD28. In contrast with°CD28, CTLA-4 
is not expressed on quiescent T cells, but CTLA-4 expres- 
sion is detectable following TCR ligation and can be further 
augmented by CD28 costimulation. At present, the role 
of CTLA-4 in costimulation is uncertain. Depending on the 
circumstances, CTLA-4 has been reported to act as an 
additional costimulatory signal or to act as a negative sig- 
nal to down-mod ulate an immune response either by termi- 
nating a proliferative response or directly inducing apop- 
tosis. A soluble recombinant form of CTLA-4, CTLA41g, 
has been used as a competitive inhibitor f CD28 activa- 
tion. In vivo, CTLA41g treatment can suppress the ability 
to mount T cell-dependent antibody production as well 
as suppress the ability to mount a cell-mediated immune 
response against tissue grafts. 
The demonstration that CTLA41g could inhibit T cell- 
dependent immune responses that were not inhibited by 
B7-1 antibodies, as well as the recognition that mice defi- 
cient in B7-1 could still induce CD28 costimulation, re- 
sulted in the discovery of a second ligand for the CD28 
receptor, B7-2. Although B7-2 shares only 26% amino acid 
identity with B7-1, B7-2 is also a member of the immuno- 
globulin gene superfamily and appears to be (~losely linked 
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Figure 1. Potential Model for the Role of Costimulation i  the Re- 
sponse of a Naive T Cell to TCR Engagement by Antigen-MHC om- 
plexes on the Surface of an APC 
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Figure 2. Schematic Model for the Activation 
and Differentiation f Th Cell Precursors into 
Thl and Th2 Effector Cells 
See text for details. Thp, Th cell precursor; 
TNF, tumor necrosis factor. 
in the genome to B7-1. B7-2 displays a different pattern 
of expression from that of B7-1. B7-2 is rapidly induced 
on the surface of activated B cells or monocytes and is 
expressed at high levels on dendritic cells. Its kinetics of 
induction suggest that B7-2 is the major CD28 ligand ex- 
pressed early during an immune response. 
Activated Th Cells Can Differentiate into Distinct 
Types of Effector Cells 
One unexplained aspect of the B7/CD28 activation path- 
way is the reason there is redundancy of both the receptors 
. and the ligands in the B7/CD28 pathway(s). Experiments 
designed to examine the differential roles of the individual 
ligands are now being reported, and the early reports are 
startling. Kuchroo et al. (1995) and Lenschow et al. (1995) 
have l"eported evidence that isolated blockade of B7-1 or 
B7-2 in vivo does not inhibit he ability to initiate an immune 
response but rather affects the type of immune response 
that develops by altering the differentiation of Th cells. 
CD4 ÷ Th cells can differentiate into either of two distinct 
types of effector cells: Thl cells, which regulate cell- 
mediated immunity, and Th2 cells, which regulate humoral 
immune responses (for review see Paul and Seder, 1994). 
Each of these two Th cell subtypes produces a distinct 
set of regulatory cytokines. Thl cells produce IL-2, y-inter- 
feron (IFNy), and tumor necrosis factor J3, while Th2 cells 
produce IL-4, IL-5, and IL-10. The differentiation of naive 
Th cells into Thl and Th2 cells has important implications 
in the immune response. In several models of autoimmune 
disease, a Th2 immune response is associated with dis- 
ease resistance while induction of a Thl response leads 
to progressive disease. In contrast, protective immunity 
from intracellular pathogens such as Leishmania major 
requires a Thl response, while a Th2 response results in 
progressive disease. 
The molecular bases for the differentiation of Th cells 
are just beginning to be delineated (Figure 2). Activation 
of precursor Th cells results in the production of IL-2 with 
relatively little IFNy or IL-4 being produced (Th0). Subse- 
quent events appear to bias the cell toward differentiation 
into a Thl or Th2 phenotype. The most effective inducers 
of such differentiation appear to be IL-12 and IL-4. Under 
the influence of I L-4, precursor cells differentiate preferen- 
tially down the Th2 pathway, while in the presence of IL-12, 
cells differentiate down the Th 1 pathway. Subsequent acti- 
vation of these differentiating cells by antigen reinforces 
these differentiation events since Th2 cells preferentially 
produce IL-4 and Thl cells produce IFNy. These lympho- 
kines in turn help perpetuate humoral and cellular immu ne 
responses, respectively. 
Several types of immune cells have been shown to be 
able to produce IL-4 during an immune response, includ- 
ing the NKI.1 subset of T cells and mast cells. IL-12 ap- 
pears to be produced primarily by monocytes, but several 
other cell types, including dendritic cells and keratino- 
cytes, can produce IL-12. The provision of either IL-12 
or IL-4 by the APC plays a strong role in biasing Th cell 
differentiation. However, even in the absence of exoge- 
nous lymphokines, T cells can be directed to either Thl 
or Th2 differentiation (Kalinski et at., 1995). High doses 
of antigen appear to favor differentiation down the Th2 
pathway, while low antigen doses appear to favor a Thl 
response (Bretscher et al., 1992). The route of antigen 
administration also appears to play an important role, per- 
haps through the recruitment of distinct populations of 
APCs (Paul and Seder, 1994). 
Costimulation by B7.1 and B7.2 Can Differentially 
Regulate Th Cell Differentiation 
Kuchroo et al. (1995) have now presented evidence that 
B7-1 and B7-2 may play distinct roles in the differentiation 
of Th cells. These investigators studied xperimental ller- 
gic encephalomylitis induced by immunization with proteo- 
lipid protein in animals simultaneously treated with either 
anti-B7-1 or anti-B7-2. Treatment with anti-B7-1 resulted in 
the generation of effector T cells that had a Th2 phenotype. 
These Th2 cells could both prevent he induction of experi- 
mental allergic encephalomylitis and abrogate stablished 
disease. In contrast, treatment with anti-B7-2 resulted in 
the production of effector cells of a Thl phenotype, re- 
sulting in increased disease severity. These data suggest 
that not only is costimulation important during the initial 
activation of uncommitted Th cells, but that costimulation 
may also play a crucial role in regulating the subsequent 
differentiation of Th0 cells along the Thl or Th2 develop- 
mental pathways. 
Other groups have also begun to report that differential 
blockade of B7-1 or B7-2 can have distinct effects on in 
vivo immune responses. Lenschow et al. (1995) have stud- 
ied the role of B7-1 and B7-2 antibodies on the develop- 
ment of autoimmune diabetes in the NOb mouse strain. 
Anti-B7-2 prevented the onset of diabetes, while treatment 
with anti-B7-1 resulted in an increased incidence and an 
accelerated course of diabetes. 
Although the findings by Kuchroo et al. (1995) and 
Lenschow et al. (1995) may initially seem contradictory, 
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both studies suggest that costimulation plays a role in the 
differentiation of Th cells. Further support for this hypothe- 
sis can be drawn from observations that Thl and Th2 re- 
sponses display differences in their dependence on co- 
stimulation (Lu et al., 1994; McKnight et al., 1994; King 
et al., 1995). For example, Corry et al. (1994) have studied 
the effect of CTLA41g treatment on the response of differ- 
ent mouse strains to L. major infection. In mice that are 
genetically predisposed to produce the Thl response to 
L. major, induction of the Thl response is not affected by 
CTLA41g treatment. This suggests that this response can 
occur under conditions of either low or no costimulation. 
In contrast, the ability of susceptible mouse strains to 
mount a Th2 response can be blocked by CTLA41g. 
Potential Mechanisms for the Differential 
Regulation of Thl/Th2 Development 
by B7.1 and B7.2 
There are several mechanisms by which the two costimu- 
latory ligands may have a differential effect on Th cell 
differentiation. Based on the relative timing of their expres- 
sion, B7-2 may be the physiologic ligand for CD28, while 
B7-1 is primarily a ligand for CTLA-4. However, Linsley et 
al. (1994) failed to find evidence for differential pairing of 
the proteins. They found that B7-1 and B7-2 display similar 
avidity for CD28. Both B7-1 and B7-2 display higher avidity 
for CTLA-4, although B7-2 binding to CTLA-4 displays 
more rapid dissociation kinetics than B7-1. An alternative 
possibility suggested by Kuchroo et al. (1995) is that B7-1 
and B7-2 engage CD28 in distinct ways that result in differ- 
ences in receptor signal transduction. Nun,bs et al. (1994) 
have shown that differential signal transduction through 
CD28 can occur. Antibodies that cross-link CD28 induce 
activation of Ras, while costimulation by B7-1-transfected 
cells does not appear to induce Ras activation. As sug- 
gested by Lenschow et al. (1995), differences in B7-1- and 
B7-2-induced signal transduction could also be due to dif- 
ferential signaling through CTLA-4. Studies involving ani- 
mals with a germline deficiency in CTLA-4 may help to 
resolve this issue. 
There is some evidence against a role for differential 
signal transduction in explaining the differences between 
B7-1 and B7-2 costimulation. Two groups that have exam- 
ined the effects of signal transduction using B7-1 and B7-2 
transfectants have failed to find any significant differences 
in the activation of second messengers or lymphokine pro- 
duction (Lanier et al., 1995; Levine et al., 1995). While 
Freeman et al. (1995) have demonstrated that multiple 
rounds of antigen priming by B7-2-transfected cells can 
lead to a Th2 phenotype, Seder et al. (1994) have used 
B7-1-expressing cells to induce the development of Th2 
clones. These data suggest th at there is no absolute differ- 
ence in B7-1- and B7-2-initiated signaling. 
There are several additional possibilities for the differen- 
tial ability of B7-1 and B7-2 to affect Th cell differentiation. 
There are clear differences both in the timing of the expres- 
sion of B7-1 and B7-2 during an immune response as well 
as differences in their expression on different APCs (Hath- 
cock et al., 1994). Antibody blocking experiments sug- 
gested that B7-2 is the major CD28 ligand that initiates 
CD28-dependent costimulation in unprimed lymph node 
cells. In contrast, B7-1 costimulation appears to be up: 
regulated later during activation of an immune response, 
and has been proposed to be the major costimulatory li- 
gand present during persistent infections. Distinct roles 
for B7-1 and B7-2 may also result from differences in their 
relative expression on the APCs involved in T cell differen- 
tiation (Figure 2). 
B7-1 and B7-2 could also serve as counterreceptors that 
transduce distinct signals to the APC upon engagement 
by CD28 or CTLA-4. The intracellular domains of B7-1 and 
B7-2 are quite distinct and could mediate differential signal 
transduction. Such signaling could alter the APC's ability 
to function as an effector cell. Delineation of these possibil- 
ities may come from characterization of mice with germline 
deletions of the B7-1 gene, the B7-2 gene ~, or both. 
Thl and Th2 Cells Differ in their Requirements 
for Costimulation 
Experiments to define the parameters that control Th2 
development have suggested that Th2 immune responses 
are dependent on high initial antigen doses. Th2 immune 
responses also appear to be dependent on CD28 costimu- 
lation during their initiation, but thereafter appear to be 
relatively less dependent on costimulation for their mainte- 
nance (McKnight et al., 1994). A potential mechanism for 
this is the observation that CD28 costimulation is neces- 
sary for the induction of T cell sensitivity to IL-4 (McArthur 
and Raulet, 1993). Thus, CD28 costimulation is essential 
for initiating a state of responsiveness to induction of Th2 
differentiation by IL-4, but is not necessary for the mainte- 
nance of the Th2 state. In contrast, the initiation of Thl 
responses appears to be less dependent on CD28 costim- 
ulation. Thl responses can be generated in CD28-defi- 
cient animals or in animals in which CD28 costimulation 
is blocked by CTLA41g (Shahinian et al., 1993; Green et 
al., 1994). However, Thl immune responses, even when 
established, appear to be sensitive to modulation by CD28 
costimulation. Most established Thl clones~continue to 
require CD28 costimulation for activation (Allison, 1994). 
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Figure 3. The Differentiation f Th Cells May Be Influenced by the 
Strength of the Activation Signal 
In this model, the strength of the activation signal is determined by 
both the dose of antigen as well as the presence or absence of costimu- 
lation. The slope of the dose response curve may also vary with the 
magnitude of the costimulatory signal. 
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These observations uggest that B7-2, by being the pri- 
mary costimulatory ligand present in unprimed animals, 
may play a more critical role in the ability to initiate a Th2 
response, while B7-1, with its later kinetics of induction, 
may be more important in the maintenance of Thl re- 
sponses. Consistent with this hypothesis, Sayegh et al. 
(1995) have shown that delaying CTLA41g treatment until 
48 hr after renal allografting selectively spares a protective 
Th2 response while still inhibiting a Thl response. 
A possible model for how CD28 costimulation could af- 
fect the initial commitment of a naive Th cell is one in which 
Thl/Th2 differentiation is determined by the strength of 
the activation signal (Figure 3). Depending on the initial 
antigen dose, CD28 costimulation could shift the response 
to antigenic hallenge from no response to aThl  response 
or from a Thl response to a Th2 response. Depending on 
when a naive T cell is recruited into an ongoing immune 
response and the type of APC involved, the major costim u- 
latory ligand could shift from B7-2 to B7-1. Such a model 
has the potential to explain some of the seemingly para- 
doxical responses observed in response to blocking B7-1 
and B7-2 in vivo. For example, a destructive Thl response 
could either be prevented at low antigen doses by blocking 
CD28 costimulation or be shifted to a protective Th2 re- 
sponse at high antigen doses by augmenting costimu- 
lation. In addition, a protective Th2 response that is de- 
pendent on costimulation could be shifted to either a 
pathogenic Thl response or no response by blocking co- 
stimulation. 
BZICD28 Costimuletion in the Maintenance 
of Established Immune Responses 
While the activation of naive T cells is critically dependent 
on costimulatory signals, memory T cells are less depen- 
dent on costimulation for activation (Croft et al., 1994). 
These data have been interpreted to suggest that blocking 
B7-1/B7-2 costimulation would be relatively ineffective at 
blocking established or recall immune responses. One re- 
cent set of data that appears difficult to reconcile with 
the above observations is the ability of CTLA41g to block 
established autoimmune disease in NZB/NZW mice. 
These mice are studied as a murine model of systemic 
lupus erythematosus, a disease that results from the pro- 
duction of autoantibodies. B cell production of autoanti- 
bodies is believed to be dependent on Th2 cells. Finck et 
al. (1994) have demonstrated that CTLA41g treatment not 
only prevents the development of disease but can also 
abrogate disease in animals with established autoimmu- 
nity. This result would seem to contradict the proposal that 
costimulation is required during the initiation but not the 
maintenance of a Th2 immune response. However, recent 
studies of autoimmunity have suggested that autoimmune 
disease results in the sequential activation of autoreactive 
clones with differing specificities, a process referred to 
as epitope spreading. Thus, some autoimmune diseases 
may be perpetuated through the sequential activation of 
naive T cells responding to distinct autoantigens exposed 
during ongoing immune destruction. If this is the case, 
CTLA41g may block established disease by inhibiting the 
ongoing differentiation of cells into the Th2 lineage rather 
than by inhibiting established Th2 clones. 
In summary, the B7/CD28 costimulatory pathway plays 
a complex role in regulating in vivo immune responses. 
In addition to augmenting the lymphokine production and 
initial proliferation of naive T cells, the B7/CD28 costimula- 
tory pathway also appears to play an important role in 
regulating the differentiation of Th cells into Thl or Th2 
cells. A clearer understanding of these additional roles for 
the CD28/CTLA-4 receptors and the differential ways in 
which B7-1 and B7-2 affect these aspects of immune acti- 
vation will have important implications for immunotherapy. 
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